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INTRODUC TION
Multiple sclerosis (MS) is an immune-mediated, disabling disease 
which is most common in young adults [1]. The pathogenesis and 
mechanism of action of MS have been partially elucidated, al-
though many facets still remain unclear. Classically, CD4+ T cells 
and interferon gamma (IFN-γ)+ CD4+ T (T helper type 1, Th1) cells in 
particular have been named as the main perpetrator in causing MS 
lesions in the central nervous system [2]. However, other immuno-
logical subsets, like interleukin 17 (IL-17+) CD4+ T cells [3,4] CD8+ T 
cells [5,6] and B cells [5,7] have also been linked to MS.
More recently, natural killer (NK) cells are under investigation in 
MS [8]. NK cells show a strong enrichment for expression of the MS 
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Abstract
Background and purpose: Natural killer (NK) cells may play a role in multiple sclerosis 
(MS). Ratios of NK cells to CD4+ T cells have been proposed as a biomarker for the thera-
peutic effect of stem cell transplantation in MS. The objectives here were to explore the 
relevance of this ratio in MS patients by analysing NK and T cell subsets, as well as their 
prognostic value for disease activity.
Methods: Baseline peripheral blood mononuclear cells of 50 relapsing–remitting MS pa-
tients, participating in our vitamin D supplementation study (SOLARIUM), were analysed 
with flow cytometry. Disease activity was measured as new magnetic resonance imag-
ing lesions, relapses and mean plasma neurofilament light chain levels after 48 weeks of 
follow-up.
Results: The proportion of NK cells correlated negatively with CD4+ T cells (R = −0.335, 
p = 0.001) and interleukin 17A (IL-17A+) CD4+ T cells (R = −0.203, p = 0.043). Participants 
with magnetic resonance imaging activity or relapses displayed lower NK/IL-17A+ CD4+ 
T cell ratios (p =0.025 and p = 0.006, respectively). The NK/IL-17A+ CD4+ T cell ratio cor-
related negatively with neurofilament light chain levels (R = −0.320, p = 0.050). Vitamin D 
supplementation did not affect these ratios.
Conclusions: Our data suggest a protective role of an expanded NK cell compartment 
compared to the CD4+ T cell subset fractions in relapsing–remitting MS patients. NK/
CD4+ T cell ratios may be a prognostic biomarker for disease activity in MS.
K E Y W O R D S
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susceptibility genes as reported in a recent genome-wide associa-
tion study [9]. In the experimental autoimmune encephalomyelitis 
model of neuro-inflammation, both direct neurotoxic effects of in-
filtrating NK cells [10] as well as a regulatory role of NK cells in con-
trolling autoreactive T cell activation [11,12] have been postulated. 
During the treatment of people with MS with the anti-CD25 anti-
body daclizumab, a drug with notable effects in reducing relapses 
and magnetic resonance imaging (MRI) activity, an expansion of the 
CD56bright subset of NK cells was observed [13]. This subset is gen-
erally considered to fulfil an immuno-regulatory role, with one of its 
functions being the killing of (autoreactive) activated T cells [13,14]. 
As such, an inverse correlation between NK cells and pathogenic T 
cells is hypothesized and supported by the findings of daclizumab 
trials. Interestingly, Darlington et al. [15] investigated the re-emer-
gence of Th17 in relapsing–remitting (RR) MS patients after autolo-
gous hematopoietic stem cell transplantation. Although the absolute 
number of NK cells did not predict IL-17A+ Th cell levels, the ratio 
between NK cells and CD4+ T cells did correlate with lower IL-17A+ 
Th cell levels after 3 weeks, 3 months, 12 months and 21 months. 
As IL-17A+ T cells are considered to contribute to the pathogenic T 
cell response in MS [3,4] the group hypothesized that a high NK/
CD4+ T cell ratio is a biomarker of a protective constitution of the 
lymphocyte compartment in MS [15]. However, no subsets of NK 
cells or CD4+ T cells were analysed, so little can be said about the 
role of, for example, CD56bright NK cells and IL-17A+ CD4+ T cells in 
this hypothesis.
The aim is to expand upon this hypothesis by exploring the 
correlation between NK cells (and their subsets) and CD4+ T cells 
(and their subsets), and by exploring the association of their ratios 
with subsequent inflammatory disease activity in a cohort of IFN-
β-treated RRMS patients. Disease activity was defined according 
to commonly used markers, namely new or enlarging MRI lesions 
and clinical relapse. Additionally, serum levels of neurofilament light 
chain (NfL), a new biomarker for axonal damage, were measured [16].
MATERIAL S AND METHODS
Patients
The complete set of inclusion and exclusion criteria for the SOLAR 
study and its substudy SOLARIUM are described elsewhere [17,18].
In short, the SOLAR study (NCT01285401) recruited patients 
aged between 18 and 55 years diagnosed with RRMS (according to 
the McDonald criteria 2005) confirmed by typical MS findings on 
MRI. The first clinical event must have been within 5 years prior 
to screening and signs of active disease must have been present 
in the last 18 months, but no relapse in 30 days before inclusion. 
Patients were excluded if they consumed more than 1000 IU 
(25 µg) of vitamin D3 supplements. All patients received IFN-β1a 
44 µg subcutaneously three times weekly. They used IFN-β1a for 
at least 90 days but no longer than 18 months. After randomiza-
tion, the patients received either IFN-β1a and a placebo or IFN-β1a 
and vitamin D3 supplements (cholecalciferol, Vigantol® Oil, Merck 
KGaA) of 7000 IU daily for 4 weeks, followed by 14,000 IU daily up 
to week 48.
The SOLARIUM substudy recruited patients from four of the 
five participating centres in the Netherlands without adding addi-
tional inclusion or exclusion criteria; the patients were eligible when 
they agreed to participate in the substudy. Peripheral blood samples 
were collected at baseline and after 48 weeks and analysed using 
flow cytometry. Written informed consent was acquired and the 
SOLARIUM study was approved by the Ethical Committee METC-Z 
(11-T-03).
This is a further analysis of the data obtained in the SOLARIUM 
study, with the only requirement being a full measure of NK cell re-
lated markers at baseline and after 48 weeks.
For our measures of disease activity, the MRI and relapse find-
ings as described in the SOLAR study were used [18] as well as the 
NfL levels as measured from available material from the SOLAR 
study [19]. Since only 3/53 patients had more than one new MRI 
lesion within 48 weeks and 4/53 patients had more than one re-
lapse within 48 weeks, data regarding MRI activity and clinical re-
lapse were collected as a dichotomous yes/no outcome. Since this 
study included RRMS patients with a short disease duration and fol-
low-up of 48 weeks, no clinically relevant disability progression was 
expected and therefore no correlations with Expanded Disability 
Status Scale progression were analysed. Plasma NfL levels were 
measured at baseline and 48 weeks using a single molecule array 
[19] in a subgroup of patients where samples were available. Since 
the baseline and week 48 levels were highly correlated (Spearman 
rho 0.615, p < 0.001), the mean NfL level was calculated, where 
available, to report the most representative level for the 48 week 
follow-up.
Peripheral blood mononuclear cell isolation
The acquirement and analysis of peripheral blood mononuclear 
cells (PBMCs) is described elsewhere [17]. In summary, peripheral 
blood samples were collected from patients at baseline and week 
48 of treatment. Blood was collected in a 10 ml sodium heparin 
blood sampling tube (BD Biosciences) and transported to Maastricht 
University Medical Centre, The Netherlands, at room temperature. 
Within 24 h PBMCs were isolated as described in previous publica-
tions [17,20].
Flow cytometry for NK cells, T cells and subtypes
Immediately after isolation, PBMCs were stained with a cocktail of 
monoclonal antibodies. The T cell staining is described elsewhere 
[17]. In short, PBMCs were stained with a cocktail of monoclonal 
antibodies to define, amongst others, CD3+ T cells, CD3+ CD4+ T 
cells and Treg cells. Cytokine expression of IFN-γ and IL-17A by 
CD3+ CD4+ T cells was assessed after a 5 h in vitro activation with 
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phorbol 12-myristate 13-acetate (50 ng/ml, Sigma Aldrich) and iono-
mycin (1 μg/ml, Sigma Aldrich) in the presence of monensin (1.25 μg/
ml, BD Biosciences). Expression of IL-10 was assessed after similar 
activation but without the addition of monensin [21].
The NK cell staining consisted of NKp46-Horizon (Biolegend); 
CD56-PE (BD Biosciences); CD3-PerCP (BD Biosciences); NKG2D-
APC (Biolegend); and CD16-PE-Cy7 (BD Biosciences). For fluores-
cence-activated cell sorting (FACS) analysis (FACS Canto II flow 
cytometer, BD Biosciences), NK cells were analysed for 100,000 
events in the lymphocyte gate.
FACS DIVA software (BD Biosciences) was used to analyse 
the flow cytometry data. To identify both NK cell subsets, first 
CD3−NKp46+ cells (NK cells) were gated by accepting some con-
tamination with CD3−NKp46− cells, because there is some overlap 
between both CD3− subsets. In order to adjust for this contam-
ination, the total NK cell population was defined as the sum of 
CD56bright CD16− and CD56dim CD16− NK cells. Gating strategies are 
shown in Figure 1a.
Additional laboratory findings
During the SOLARIUM study, total white blood cell counts were 
gathered to calculate absolute numbers of lymphocyte subsets 
(Covance) [17]. These white blood cell counts were now used to 
calculate absolute cell numbers for subtypes. NfL levels were meas-
ured in plasma in duplicate with a single molecule array (Simoa) [19].
Statistical analysis
SPSS software (IBM SPSS, version 25.0) was used to assess the cor-
relation between various NK cell subsets and T cell subsets, as well 
as the prognostic value of NK/T ratios and their subtypes for clinical 
outcomes and NfL levels. Normality of data was assessed by visual 
inspection of histograms with normal curves, skewness and kurto-
sis. Potential significant outliers were found using scatterplots with 
regression lines where a Cook's distance >1 was defined as a signifi-
cant outlier. When a significant outlier was found, an additional anal-
ysis was performed without the outlier. Assessment of correlations 
between NK cell and CD4+ T cell subsets was done using Pearson r 
analyses or Spearman rho analyses, depending on normality of the 
data distribution. To assess the association between ratios and MRI 
outcome/relapse outcome, independent t tests or Mann–Whitney U 
tests were performed based on the distribution of data. Since in the 
SOLAR trial the presence of combined unique active (CUA) lesions 
was influenced by treatment arm [18] a logistic regression analysis 
was conducted to correct the association between NK/T cell ra-
tios and MRI end-point for treatment arm allocation. If data were 
not normally distributed, ratios were logarithmically transformed in 
F I G U R E  1  (a) Gating strategy used to analyse NK cells and subsets. Step 1 shows the gating of lymphocytes from the PBMC population. 
Step 2 shows the gating of NK cells, defined as CD3− NKp46+. Step 3 shows the differentiation between the CD56dim CD16+ NK cells (above) 
and CD56bright CD16− NK cells (below). (b) Correlation between the percentage of CD56bright NK cells and the percentage of CD4+ T cells. 
R is Spearman’s rho. N = 100. (c) Correlation between the percentage of CD56bright NK cells and the percentage of IL17-A+ CD4+ T cells. R 
is Spearman’s rho. N = 100. (d) Heatmap of correlations between NK cells (subsets) and various T cell subsets. Correlations with a tinted 
background are statistically significant. The associations between NK cells and T cell subsets seem to be mainly caused by the CD56bright NK 
cells, despite them making up a small portion of the total NK cells. N = 100 [Colour figure can be viewed at wileyonlinelibrary.com]
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order to create normally distributed data. The presence of relapses 
[18] and plasma NfL levels [19] were no different between treatment 
arms, so no correction for these end-points was applied. The cor-
relation between ratios and NfL levels was assessed via the use of 
Pearson r or Spearman rho analyses, again based on data distribu-
tion. A p value of ≤0.05 was considered statistically significant.
RESULTS
Patient characteristics
The SOLARIUM study included 53 patients, but due to incomplete 
staining at baseline or week 48 regarding NK cell related markers, 
three patients were excluded from the current study, leaving 50 pa-
tients for analysis. Baseline patient characteristics of both treatment 
arms are described in Table 1.
Additionally, three patients did not undergo an MRI examina-
tion at week 48, leaving 47 to be analysed for MRI activity. Clinical 
disease activity markers were equally distributed between patients 
with and without MRI activity at week 48 (Table 1). NfL levels were 
measured for 35 patients at baseline and 38 patients at week 48.
Natural killer cells correlate with CD4+ and IL-
17A+ CD4+ T cells
To explore the relationship between circulating NK and T 
cells, correlations were calculated between total NK cells, 
CD56bright NK cells and CD56dim NK cells, on the one hand, and 
CD4+ T cells, CD8+ T cells, IL-17A+ CD4+ T cells, IFN-γ+ CD4+ 
T cells, IL-10+ CD4+ T cells and Tregs on the other. Most nota-
bly, CD56bright NK cells correlated negatively with CD4+ T cells 
(R = −0.335, p = 0.001) and CD4+ IL-17A+ T cells (R = −0.203; 
p = 0.043) (shown in Figure 1b,c). Correlations between the 
CD56bright NK cell fraction and T cell subsets were more promi-
nent compared to the CD56dim NK cell fraction (Figure 1d). These 
findings suggest that there is a biological association between 
NK and T cell proportions, supporting the assessment of ratios 
as proposed by Darlington et al. [15] Furthermore, these data 
suggest that the CD56bright NK cell subset is the most influential 
subset in these associations.
NK/CD4+ T cell subset ratios are lower in patients 
with new MRI lesions
To explore the relevance of NK/T cell subset ratios in the course 
of MS, the association of these ratios with the presence of new or 
enhancing MRI lesions (CUA) were assessed after 48 weeks’ follow-
up as the most sensitive marker for inflammatory disease activity 
[22]. When focusing on total CD4+ T cells, the total NK/CD4+ T cell 
ratio and the CD56dim/CD4+ T cell ratio were significantly lower in 
the group with MRI activity (p = 0.050, corrected for treatment arm 
p = 0.071, and p = 0.050, corrected for treatment arm p = 0.061; 
Figure 2a). Similarly, when analysing IL-17A+ CD4+ T cells, patients 
with CUA lesions had a lower total NK/IL-17A+ CD4+ T cell ratio 
(p = 0.025, corrected for treatment arm p = 0.029) and CD56dim NK/
TA B L E  1  Baseline characteristics of study participants, as well as a comparison of baseline characteristics between patients with and 
without MRI activity
RRMS patients (N = 50) No MRI activity MRI activity p value
Sex (N, %)
Female 33 (66) 25 (69) 5 (45) 0.171
Male 17 (34) 11 (31) 6 (55)
Age (years, median, interquartile range) 37.2 (31.7–44.3) 40.0 (32.8–45.3) 36.2 (29.6–43.9) 0.291
Body mass index (N, %)
≥25 kg/m2 28 (56) 19 (53) 7 (64) 0.731
<25 kg/m2 22 (44) 17 (47) 4 (36)
Disease duration (months, median, interquartile range) 7.4 (4.5–12.3) 7.3 (4.6–12.8) 8.4 (4.3–12.3) 0.851
Attacks during past 2 years at baseline (N, %)
>1 16 (32) 11 (31) 4 (36) 0.725
≤1 34 (68) 25 (69) 7 (64)
Duration since last attack at baseline (months, median,  
interquartile range)
7.6 (5.0–10.5) 7.4 (4.4–10.4) 8.0 (7.2–11.3) 0.386
Treatment (N, %)
Placebo 21 (42) 11 (31) 8 (73) 0.018
Vitamin D3 29 (58) 25 (69) 3 (27)
Note: Analysis of continuous data is done with a Mann–Whitney U test. Analysis of dichotomous data is done with Fischer's exact test.
Abbreviations: MRI, magnetic resonance imaging; RRMS, relapsing–remitting multiple sclerosis.
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F I G U R E  2  (a) Differences in NK cell/CD4+ T cell ratio, CD56bright NK cell/CD4+ T cell ratio and CD56dim NK cell/CD4+ T cell ratio between 
patients with and without MRI activity after 48 weeks of follow-up. p value is calculated using a Mann–Whitney U test. Bars represent 
median with interquartile range. N = 47. (b) Differences in NK cell/IL-17A+ CD4+ T cell ratio, CD56bright NK cell/IL-17A+ CD4+ T cell ratio 
and CD56dim NK cell/IL-17A+ CD4+ T cell ratio between patients with and without MRI activity after 48 weeks of follow-up. p value is 
calculated using a Mann–Whitney U test. Bars represent median with interquartile range. N = 47. (c) Differences in NK cell/IL-17A+ CD4+ 
T cell ratio, CD56bright NK cell/IL-17A+ CD4+ T cell ratio and CD56dim NK cell/IL-17A+ CD4+ T cell ratio between patients suffering one or 
more relapses or no relapse during the 48 week follow-up period. p value is calculated using a Mann–Whitney U test. Bars represent median 
with interquartile range. N = 50. (d) Correlations between NK cell/IL-17A+ CD4+ T cell ratio, CD56bright NK cell/IL-17A+ CD4+ T cell ratio and 
CD56dim NK cell/IL-17A+ CD4+ T cell ratio at baseline and mean NfL values measured in pg/ml. R is Spearman’s rho. N = 38
NK cells / IL-17A+CD4+ T cells
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IL-17A+ CD4+ T cell ratio (p = 0.021, corrected for treatment arm 
p = 0.026) (Figure 2b).
NK/IL-17A+ CD4+ T cell ratios are lower in patients 
with subsequent relapses
To explore the consistency of this finding, other markers of dis-
ease activity were analysed. First, patients who experienced 
a clinical exacerbation during the 48 week follow-up period 
were compared with patients who did not experience a relapse 
(Figure 2c). Focusing on the ratios most clearly associated with 
radiological disease activity, a trend towards a lower CD56bright 
NK/IL-17A+ CD4+ T cell ratio was found, whereas significantly 
lower total NK/IL-17A+ CD4+ T cell (p = 0.006) and CD56dim NK/IL-
17A+ CD4+ T cell ratios (p = 0.005) were observed in patients with 
exacerbations of disease.
NK/CD4+ T cell subset ratios are negatively 
correlated with NfL
Plasma NfL is a measure of clinical and MRI disease activity in MS, 
and strongly correlates with enhancing MRI lesions [16,23]. Baseline 
total NK and CD56dim NK/IL-17A+ CD4+ ratios were negatively cor-
related with mean NfL levels (R = −0.320, p = 0.050; and R = −0.322, 
p = 0.049; Figure 2d). Notably, the same data point in all three cor-
relation plots is a significant outlier (Cook's distance >1). Correlation 
F I G U R E  3  (a) Correlation between 25(OH)D levels at baseline and NK cell/IL-17A+ CD4+ T cell ratio, CD56bright NK cell/IL-17A+ CD4+ T 
cell ratio and CD56dim NK cell/IL-17A+ CD4+ T cell ratio. R is Spearman’s rho. N = 50. (b) Comparison of NK cell/IL-17A+ CD4+ T cell ratio, 
CD56bright NK cell/IL-17A+ CD4+ T cell ratio and CD56dim NK cell/IL-17A+ CD4+ T cell ratio at week 48 between patients receiving a placebo 
or vitamin D3 supplements. p value is calculated using a Mann–Whitney U test. Bars represent median with interquartile range. N = 50. 
(c) Comparisons of the evolutions of NK cell/IL-17A+ CD4+ T cell ratio, CD56bright NK cell/IL-17A+ CD4+ T cell ratio and CD56dim NK cell/
IL-17A+ CD4+ T cell ratio. Evolution was calculated by dividing the ratio at week 48 by the ratio at baseline. An evolution >1 means the ratio 
has increased after 48 weeks, whereas a ratio <1 means the ratio has decreased. p value is calculated using a Mann–Whitney U test. Bars 
represent median with interquartile range. N = 50
NK cells / IL-17A+CD4+ T cells
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analyses without this significant outlier were more clearly support-
ive of a negative correlation for IL-17A+ CD4+ in a ratio with NK cells 
(R = −0.422, p = 0.009), CD56bright cells (R = −0.352, p = 0.033) and 
CD56dim cells (R = −0.424, p = 0.009).
NK/CD4+ subset ratios are not correlated with 
vitamin D
Low serum 25-hydroxyvitamin D (25(OH)D) levels are a biomarker 
for a higher risk of subsequent relapses [24]. First, baseline 25(OH)
D did not significantly correlate with baseline NK/CD4+ T cell sub-
set ratios (Figure 3a). Then, in order to assess an effect of vita-
min D supplementation on NK/CD4+ T cell subset ratios, ratios at 
week 48 were compared between treatment arms, which did not 
show any influence of vitamin D3 supplementation (Figure 3b). 
Additionally, the relative increase or decrease in these ratios dur-
ing 48 weeks of follow-up was analysed, stratified for treatment 
arm. There was no significant difference in distribution of any of 
the NK/CD4+ T cell subset ratios between vitamin D3 and the pla-
cebo arm (Figure 3c). Also, the relative and absolute NK cell (sub-
set) proportions were not different between the treatment arms 
(Figure S1).
DISCUSSION
The prognostic value of NK/CD4+ T cell subset ratios was investi-
gated for disease activity in a cohort study of a homogeneous group 
of INF-β-treated early RRMS patients.
First, an association was found between the relative presence of 
NK cells and the relative presence of CD4+ T cells and IL-17A+ CD4+ 
T cells. This association is also found with NK cell subsets, where the 
CD56bright subset of NK cells shows a stronger association than the 
CD56dim subset, despite it making up a relatively small portion of the 
total NK cell population. This stronger association with CD56bright 
NK cells may support the hypothesis of CD56bright NK cells fulfilling 
an immuno-regulatory role in MS by suppressing (autologous) acti-
vated T cells, as seen in daclizumab trials [13].
Secondly, the relative presence of NK cells and subsets compared 
to CD4+ T cells and IL-17A+ CD4+ T cells, expressed as a ratio, seems 
to be relevant for disease activity. Indeed, NK/CD4+ T cell subset ra-
tios are lower in patients with new and/or enlarging MRI lesions after 
48 weeks of follow-up. This effect is seen in ratios including CD4+ T 
cells and, perhaps more specifically, in ratios including IL-17A+ CD4+ 
T cells. IL-17A+ CD4+ T cells have been argued to constitute a subset 
involved in the pathogenesis of MS [25–28] although other subsets 
based on other cytokines and surface markers have been shown to 
be involved as well. Nevertheless, our findings do reinforce the idea 
of an IL-17A+ CD4+ T cell contribution to MS disease activity, and also 
support a regulatory effect of NK cells on IL-17A+ CD4+ T cells, as 
suggested by Darlington et al. [15] and daclizumab trials [29]. When 
specifically looking at the NK cell subsets, the prognostic value for 
disease activity seems predominantly driven by the CD56dim NK cell 
ratios. Given that the CD56bright NK cell subset is generally consid-
ered to be the regulatory subset and CD56bright NK cells correlate 
negatively with IL-17A+ CD4+ T cell proportions, our clinical asso-
ciations seem to be conflicting with this concept [8]. However, not 
only CD56bright NK cells but also CD56dim NK cells show a capability 
to kill activated T cells [30]. Over the last few years, CD56bright NK 
cells have been the main focus for NK cell research in MS, but our 
findings highlight that the CD56dim population may be an important 
facet as well.
Our exploratory cohort study has some limitations. First, the 
SOLAR study was originally designed to investigate the effect of 
high-dose vitamin D3 treatment [18] whilst the SOLARIUM sub-
study was initiated to unravel the effect of high-dose vitamin D3 
supplementation on the immune system [17]. This is also the rea-
son for some missing data, in particular for NfL measurements [19]. 
Furthermore, MS patients included were selected based on having 
RRMS, short disease duration and treatment with IFN-β. Therefore, 
extrapolation of the data requires extension of our findings in other 
MS patient cohorts. Finally, due to the initial research question of 
the SOLAR study, the number of patients is not based on a power 
calculation relevant to our question. Hence, our study is referred to 
as an exploratory study.
Interestingly, it has been shown in daclizumab studies that IL-2 
is important in the interplay between NK and T cells [31] and other 
studies have shown that granulocyte-macrophage colony-stimu-
lating factor (GM-CSF), a pro-inflammatory cytokine, is strongly 
induced by IL-2 [32]. Unfortunately, it was not possible to evaluate 
GM-CSF+ CD4+ T cells due to too many missing data points at base-
line [17]. Thus, the possible relation between GM-CSF, IL-2 and NK 
cells could not be investigated in this study.
In conclusion, a relation between NK cells (subsets) and CD4+ T 
cells (subsets) in RRMS was shown. NK cells seem to exert a protec-
tive effect, hypothetically by controlling the T cell population. Not 
only is the CD56bright NK cell population, known for its immuno-reg-
ulatory properties, involved, but also the CD56dim NK cell population 
seems to play a role in reducing disease activity. More research with 
independent datasets is needed to confirm the validity and use of 
NK/CD4+ subset ratios as a prognostic marker in RRMS.
ACKNOWLEDG EMENTS
The participants of this study are thanked for their participation. 
This study was funded by the Nationaal MS Fonds grant OZ2016-
001 and an unrestricted grant by Merck.
CONFLIC T OF INTERE S TS
MM, JD, AM and LR have nothing to disclose; OG received travel 
support, speaker honorarium and/or served on advisory boards 
for Biogen, Merck, Sanofi Genzyme and TEVA; JK received travel 
support, research support, speaker fees and/or served on advisory 
boards for ECTRIMS, Swiss MS Society, Swiss National Research 
Foundation (320030_160221), University of Basel, Teva, Roche, 
Protagen AG, Novartis, Merck, Genzyme, Biogen and Bayer; RH 
908  |    MIMPEN Et al.
received institutional research grants and fees for lectures and 
advisory boards from Biogen, Merck and Genzyme-Sanofi; JS re-
ceived lecture and/or consultancy fees from Biogen, Merck, Sanofi 
Genzyme and Novartis.
E THIC AL S TATEMENT
Our data have not been submitted or published elsewhere, all au-
thors agree with submission, financial conflicts of interest and 
funding are disclosed, no animal studies were conducted. Our re-
search is based on human studies, which were approved by the local 
Ethical Committee. Informed consent from all participating subject 
was obtained. This study was funded by Nationaal MS Fonds grant 
OZ2016-001 and an unrestricted grant by Merck.
AUTHOR CONTRIBUTIONS
MM contributed to the writing of the article and statistical analyses 
performed. JD was involved in writing and gave expert opinions on 
the immunological basis of the paper. AM and LR were involved in 
gathering and analysing blood samples and creating the database 
from which our T cell data is derived. OG was involved in writing 
and the general outline of the paper. JK was involved in the general 
outline of the paper and provided expert opinions on the basis of 
neurofilament light chain. RH contributed in the general outline of 
the paper and provided financial support. JS contributed to writing, 
statistics, and the general outlines of the paper.
DATA AVAIL ABILIT Y S TATEMENT
The data that support the findings of this study are available from 
the corresponding author upon reasonable request.
ORCID
Max Mimpen  https://orcid.org/0000-0003-2009-7199 
Joost Smolders  https://orcid.org/0000-0001-9766-8661 
R E FE R E N C E S
 1. Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 
2019;26:27-40.
 2. Gutcher I, Becher B. APC-derived cytokines and T cell polar-
ization in autoimmune inflammation. J Clin Invest. 2007;117: 
1119-1127.
 3. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regu-
lates tissue inflammation by producing interleukin 17. Nat Immunol. 
2005;6:1133-1141.
 4. van Langelaar J, van der Vuurst de Vries RM, Janssen M, et al. 
T helper 17.1 cells associate with multiple sclerosis disease 
activity: perspectives for early intervention. Brain. 2018;141: 
1334-1349.
 5. Machado-Santos J, Saji E, Troscher AR, et al. The compartmental-
ized inflammatory response in the multiple sclerosis brain is com-
posed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 
2018;141:2066-2082.
 6. Salou M, Nicol B, Garcia A, Laplaud DA. Involvement of CD8(+) T 
cells in multiple sclerosis. Front Immunol. 2015;6:604.
 7. Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in 
multiple sclerosis. Nat Immunol. 2018;19:696-707.
 8. Mimpen M, Smolders J, Hupperts R, Damoiseaux J. Natural killer 
cells in multiple sclerosis: a review. Immunol Lett. 2020;222:1-11.
 9. International Multiple Sclerosis Genetics C. Multiple sclerosis ge-
nomic map implicates peripheral immune cells and microglia in sus-
ceptibility. Science. 2019;365:eaav7188.
 10. Liu Q, Sanai N, Jin WN, La Cava A, Van Kaer L, Shi FD. Neural stem 
cells sustain natural killer cells that dictate recovery from brain in-
flammation. Nat Neurosci. 2016;19:243-252.
 11. Leavenworth JW, Schellack C, Kim HJ, Lu L, Spee P, Cantor H. 
Analysis of the cellular mechanism underlying inhibition of EAE 
after treatment with anti-NKG2A F(ab’)2. Proc Natl Acad Sci U S A. 
2010;107:2562-2567.
 12. Lu L, Ikizawa K, Hu D, Werneck MB, Wucherpfennig KW, Cantor 
H. Regulation of activated CD4+ T cells by NK cells via the Qa-1-
NKG2A inhibitory pathway. Immunity. 2007;26:593-604.
 13. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory 
CD56(bright) natural killer cells mediate immunomodulatory ef-
fects of IL-2Ralpha-targeted therapy (daclizumab) in multiple scle-
rosis. Proc Natl Acad Sci U S A. 2006;103:5941-5946.
 14. Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for gran-
zyme K in CD56bright NK cell-mediated immunoregulation of mul-
tiple sclerosis. J Immunol. 2011;187:781-790.
 15. Darlington PJ, Stopnicki B, Touil T, et al. Natural killer cells regu-
late Th17 cells after autologous hematopoietic stem cell trans-
plantation for relapsing remitting multiple sclerosis. Front Immunol. 
2018;9:834.
 16. Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament 
light chain as a biomarker of MS disease activity and treatment re-
sponse. Neurology. 2019;92:e1007-e1015.
 17. Muris AH, Smolders J, Rolf L, et al. Immune regulatory effects of 
high dose vitamin D3 supplementation in a randomized con-
trolled trial in relapsing remitting multiple sclerosis patients 
receiving IFNbeta; the SOLARIUM study. J Neuroimmunol. 
2016;300:47-56.
 18. Hupperts R, Smolders J, Vieth R, et al. Randomized trial of daily 
high-dose vitamin D3 in patients with RRMS receiving subcutane-
ous interferon beta-1a. Neurology. 2019;93:e1906-e1916.
 19. Smolders J, Mimpen M, Oechtering J, et al. Vitamin D3 supple-
mentation and neurofilament light chain in multiple sclerosis. Acta 
Neurol Scand. 2020;141:77-80.
 20. Smolders J, Thewissen M, Peelen E, et al. Vitamin D status is pos-
itively correlated with regulatory T cell function in patients with 
multiple sclerosis. PLoS One. 2009;4:e6635.
 21. Muris AH, Damoiseaux J, Smolders J, Cohen Tervaert JW, Hupperts 
R, Thewissen M. Intracellular IL-10 detection in T cells by flow cy-
tometry: the use of protein transport inhibitors revisited. J Immunol 
Methods. 2012;381:59-65.
 22. Barkhof F, Simon JH, Fazekas F, et al. MRI monitoring of immuno-
modulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol. 
2011;8:13-21.
 23. Gafson AR, Barthelemy NR, Bomont P, et al. Neurofilaments: 
neurobiological foundations for biomarker applications. Brain. 
2020;143:1975-1998.
 24. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin 
D is associated with lower relapse risk in multiple sclerosis. Ann 
Neurol. 2010;68:193-203.
 25. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in mul-
tiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 
2009;65:499-509.
 26. Hu D, Notarbartolo S, Croonenborghs T, et al. Transcriptional signa-
ture of human pro-inflammatory TH17 cells identifies reduced IL10 
gene expression in multiple sclerosis. Nat Commun. 2017;8:1600.
 27. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes 
promote blood–brain barrier disruption and central nervous system 
inflammation. Nat Med. 2007;13:1173-1175.
 28. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 produc-
tion in central nervous system-infiltrating T cells and glial cells is 
    |  909NK/T RATIOS AS A PROMISING BIOMARKER FOR DISEASE ACTIVITY
associated with active disease in multiple sclerosis. Am J Pathol. 
2008;172:146-155.
 29. Bielekova B, Richert N, Herman ML, et al. Intrathecal ef-
fects of daclizumab treatment of multiple sclerosis. Neurology. 
2011;77:1877-1886.
 30. Nielsen N, Odum N, Urso B, Lanier LL, Spee P. Cytotoxicity of 
CD56(bright) NK cells towards autologous activated CD4+ T cells 
is mediated through NKG2D, LFA-1 and TRAIL and dampened via 
CD94/NKG2A. PLoS One. 2012;7:e31959.
 31. Bielekova B. Daclizumab therapy for multiple sclerosis. Cold Spring 
Harb Perspect Med. 2019;9:a034470.
 32. Hartmann FJ, Khademi M, Aram J, et al. Multiple sclerosis-associ-
ated IL2RA polymorphism controls GM-CSF production in human 
TH cells. Nat Commun. 2014;5:5056.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Mimpen M, Muris AH, Rolf L, et al. 
Prognostic value of natural killer cell/T cell ratios for disease 
activity in multiple sclerosis. Eur J Neurol. 2021;28:901–909. 
https://doi.org/10.1111/ene.14680
